Meeting
2011 ASCO Annual Meeting
Clinical significance of tumor markers as prognostic factors in patients with metastatic gastric cancer receiving first-line chemotherapy.
Authors
J. Jo
Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
J. Jo , M. Ryu , D. Koo , B. Ryoo , H. J. Kim , J. Lee , H. Chang , T. W. Kim , K. D. Choi , G. H. Lee , H. Jung , K. C. Kim , J. H. Yook , S. T. Oh , B. S. Kim , J. Kim , Y. Kang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal, Gastric, or Small Bowel
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4035)
Abstract #
4035
Poster Bd #
23C
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Analysis of prognostic factors in locally advanced and metastatic pancreatic cancer treated with gemcitabine or gemcitabine and S-1 chemotherapy using individual patient data from three randomized studies.
First Author: Yousuke Nakai
Poster
2014 Gastrointestinal Cancers Symposium
Evaluation of usefulness of Royal Marsden Hospital prognostic index in second-line chemotherapy of advanced gastric cancer.
First Author: Takahide Sasaki
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.
First Author: Kohei Shitara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.
First Author: Lin Shen